^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations
Published date:
04/05/2023
Excerpt:
Osimertinib combined with bevacizumab shows promising results in EGFR-mutated NSCLC patients with brain metastasis, and the side effects are tolerable.
DOI:
10.1111/1759-7714.14880
Trial ID:
Source:
Title:
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
Excerpt:
...- EGFR mutation , the EGFR status was identified from primary lung tumors using the amplification refractory mutation system (ARMS) or next-generation sequencing (NGS) analysis....
Trial ID:
Source:
Title:
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
Excerpt:
...- EGFR mutation , the EGFR status was identified from primary lung tumors using the amplification refractory mutation system (ARMS) or next-generation sequencing (NGS) analysis....
Trial ID:
More C2 evidence
Source:
Title:
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
Excerpt:
...Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation Participant must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1....
Trial ID:
Source:
Title:
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
Excerpt:
...Documented EGFR exon 21 L858R mutation 7....
Trial ID:
Source:
Title:
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Excerpt:
...Participant must have histologically or cytologically confirmed, metastatic, nonsquamous non-small cell lung cancer (NSCLC) Partipiant harboring primary epidermal growth factor receptor (EGFR) Exon 18-21 mutation and brain metastasis....
Trial ID:
Source:
Title:
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Excerpt:
...- Somatic activating mutation in EGFR...
Trial ID:
Source:
Title:
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
Excerpt:
...The tumor harbors epidermal growth factor receptor (EGFR) mutations(include 19del, L858R, T790M, G719X, L861Q, S768I, 20 A763-Y764ins), and at least concurrent with TP53 6....
Trial ID:
Less C2 evidence
Source:
Title:
Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutated NSCLC with brain metastasis instructed by dynamic monitoring circulating tumor DNA of paired cerebrospinal fluid and plasma.
Published date:
05/25/2023
Excerpt:
Patients with EGFR-positive NSCLC and brain metatases were treated with osimertinib (80mg, daily) plus bevacizumab (5mg/kg, every 4 week) as the first-line treatment…. The median CNS progression-free survival was 15.5 months (6.8 months to not reached). The CNS objective response rate was 93.33%. Six patients received gamma knife radiotherapy before Osimertinib, the median CNS progression-free survival was 14 months (6.8 months to not reached), the CNS objective response rate was 100%.
DOI:
10.1200/JCO.2023.41.16_suppl.e21182
Source:
Title:
Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
Published date:
10/14/2022
Excerpt:
This single-arm, open-label, phase 2 study aimed to investigate the clinical benefits of the bevacizumab (15 mg/kg) and osimertinib (80 mg) combination in the first-line setting for advanced EGFR-mutated NSCLC with MPE....The median PFS was 8.5 months (95% confidence interval [CI]: 5.3–11.3), the 1-year PFS was 32.1% (80% CI: 21.4–43.3), and the objective response rate was 74.2% (95% CI: 56.8–86.3).
DOI:
https://doi.org/10.1016/j.jtocrr.2022.100424
Source:
Title:
EP13.01-002 Radiomic Signature on CT Images: A Noninvasive Biomarker for Pretreatment Discrimination of EGFR Mutations in NSCLC Patients
Published date:
07/12/2022
Excerpt:
From April 1, 2018, to January 1, 2021, a total of 31 patients with metastatic EGFR-mutant lung cancers were enrolled in this study. Osimertinib was orally administered daily (once) at a dose of 80 mg...Bevacizumab (7.5 mg/kg) was administered by drip infusion on the first day of each cycle....Of the 26 patients, 6 (23.08%) had a partial response, 20 (72.92%) had stable disease, and none had progressive disease....EGFR21 had a significantly higher risk of progression than EGFR19 (HR=6.998, 95% CI: 2.101-23.311, P=0.002).
Source:
Title:
Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
Published date:
03/14/2022
Excerpt:
We retrospectively reviewed the data from 27 LM patients with EGFR-mutant NSCLC who received osimertinib with or without bevacizumab...The median overall survival (OS) of the patients who received osimertinib and bevacizumab (n = 16) compared with osimertinib group (n = 11) was 18.0 months versus 13.7 months (log-rank test, p = 0.046, HR = 2.867, 95% CI 1.007–8.162).
DOI:
https://doi.org/10.1186/s12967-022-03331-9
Source:
Title:
1216P-Effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated advanced non-small cell lung cancer with brain metastases
Published date:
09/13/2021
Excerpt:
All the patients were evaluable and showed partial response (PR) when make efficacy evaluation at the first time….Osimertinib in combination with chemotherapy and Bevacizumab exhibits superior activity and generally manageable toxicities for the EGFR-mutated advanced NSCLC patients with brain metastases...
Secondary therapy:
Chemotherapy
Source:
Title:
Effectiveness of osimertinib plus chemotherapy and avastin for untreated EGFR-mutated advanced non-small cell lung cancer.
Published date:
05/19/2021
Excerpt:
...22 patients diagnosed with untreated advanced NSCLC and tested with EGFR mutation, who received osimertinib ( 80mg QD) plus pemetrexed (500mg/m2), cisplatin (75mg/m2)and bevacizumab...All the patients were evaluated and showed partial response(PR) when make efficacy evaluation at the first time....Osimertinib in combination with chemotherapy and Bevacizumab. exhibits superior activity and generally manageable toxicities for the naive advanced NSCLC patients with EGFR mutant...
Secondary therapy:
cisplatin + pemetrexed
DOI:
10.1200/JCO.2021.39.15_suppl.e21178
